AbbVie beats Q2 revenue, adjusted EPS estimates but cuts FY adj EPS guidance

AbbVie

31/07/2026 12:59

Overview
U.S. pharmaceutical firm's Q2 revenue rose 10% and beats analyst expectations
Adjusted EPS for Q2 rose ~23% and beat analyst expectations

Outlook
AbbVie updates 2026 adj diluted EPS guidance to $13.87-$14.07 from $13.91-$14.11
Company expects Apogee acquisition to be $0.14 per share dilutive to 2026 EPS
AbbVie 2026 EPS guidance includes $0.58 per share unfavorable impact from acquired IPR&D

Result Drivers
IMMUNOLOGY GROWTH - Higher Skyrizi and Rinvoq sales drove immunology portfolio revenue up 15%, offsetting a steep decline in Humira
NEUROSCIENCE EXPANSION - Neuroscience portfolio revenue rose 20%, led by Vraylar, Botox Therapeutic, and migraine treatments
ONCOLOGY AND AESTHETICS WEAKNESS - Oncology revenue declined 1.5% and aesthetics grew only 0.3%, with Imbruvica and Juvederm sales falling

Company press release: ID:nPn7RL9sa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Revenue
Beat
$16.99 bln
$16.77 bln (21 Analysts)
Q2 Adjusted EPS
Beat
$3.65
$3.60 (17 Analysts)
Q2 EPS
 
$2.03
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 26 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Abbvie Inc is $275.50, about 7% above its July 30 closing price of $257.41
The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 15 three months ago

Reuters Recommended Reads
July 30 - Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results
July 30 - Regeneron Q2 revenue beats on higher Dupixent, Eylea HD sales
July 30 - France's Sanofi Q2 revenue rises 17.8%, beats estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)